PT-141 (Bremelanotide) Research Guide: Melanocortin System, Sexual Function Biology, and MC4R Pharmacology

By Sam Smith

PT-141 reached FDA approval in 2019 as Vyleesi — the first non-hormonal, centrally-acting treatment for hypoactive sexual desire disorder in premenopausal women. That distinction matters more than it might seem. Every approved treatment for sexual dysfunction before it — sildenafil, tadalafil, testosterone preparations — works peripherally, targeting vascular smooth muscle or hormone levels. PT-141 (bremelanotide) works in the brain, activating melanocortin MC3R and MC4R receptors in the hypothalamus to generate sexual arousal through a central pathway that doesn't require the physical preconditions that PDE5 inhibitors depend on. For men who don't respond adequately to Viagra or Cialis — including those with psychogenic erectile dysfunction — that mechanistic difference has real clinical relevance.

The backstory here is worth knowing. PT-141 was derived from Melanotan II, a synthetic analog of alpha-MSH developed initially as a potential tanning agent. Researchers noticed that Melanotan II produced spontaneous erections as a prominent side effect in male study subjects — which quickly redirected the research program toward sexual function. The selective MC receptor profile of PT-141 (it hits MC3R and MC4R, not MC1R, which drives pigmentation) was engineered to separate sexual arousal effects from the tanning and melanin-deposition effects of its parent compound. In published studies, the peptide produces measurable increases in genital arousal and subjective sexual desire within 45 to 60 minutes of subcutaneous injection, with effects lasting several hours.

This guide covers how PT-141 works at the melanocortin receptor level, what the human trial data shows on onset, duration, and efficacy across genders, how it compares with PDE5 inhibitors, documented side effects including nausea and transient blood pressure changes, and what researchers should know about sourcing and administration.

What does the PT-141 peptide do?

PT-141 is a synthetic peptide agonist of melanocortin receptors, primarily MC3R and MC4R, with no significant activity at the muscle-relaxant PDE5 pathway. The compound was developed at Palatin Technologies from melanotan-II by removing the cyclising disulfide and adjusting the C-terminus for selective MC4R signalling. Published research shows that several other melanocortinergic agents including HP-228, THIQ, and bremelanotide (PT-141) share the same scaffold class and target the same central pathways.

Once injected, PT-141 crosses the blood-brain barrier and binds MC4R-expressing neurons in the hypothalamus and brainstem. Published research shows that MC4R is predominantly expressed in the medial preoptic area (mPOA) of the hypothalamus, a region long associated with the central control of sexual desire and motivation. Downstream, MC4R activation in the mPOA increases dopamine release in the nucleus accumbens, providing the reward-circuit signal that drives sexual arousal.

Mechanism: MC3R, MC4R, and central sexual arousal

The mechanism is entirely central. Published research shows that knockout and conditional-allele studies specifically implicate the melanocortin 4 receptor (MC4R) in the central control of sexual function, ruling out a peripheral vascular contribution. Published data confirms that melanocortin receptors in the forebrain and spinal cord can be activated to produce erectile responses independently of phosphodiesterase-mediated vasodilation, which is the operational difference between this peptide and PDE5 inhibitors.

In animal models, the effect is reproducible. Published research shows that administration of PT-141 to rats and nonhuman primates results in penile erections in a dose-dependent fashion, with effects observed across multiple dose ranges by subcutaneous and intranasal routes. The same studies show MC3R/MC4R-mediated effects on grooming, sexual approach behaviour, and proceptive responses in female rodents.

How long does PT-141 take to work?

Onset times in published human trials sit between 30 and 60 minutes after subcutaneous injection. Peak plasma bremelanotide concentration is reached within roughly 60 to 90 minutes, with the sexual arousal effect peaking shortly after. Duration of effect is approximately 8 to 12 hours in the published trials, longer than typical PDE5-inhibitor windows. Intranasal formulations show somewhat faster onset (15 to 30 minutes) but lower bioavailability.

Is PT-141 better than Viagra or Cialis?

“Better” depends on the underlying biology. PDE5 inhibitors (Viagra, Cialis) work peripherally by blocking phosphodiesterase-5 in the corpus cavernosum, enabling cGMP-driven smooth-muscle relaxation in response to existing arousal cues. PT-141 works centrally by activating melanocortin receptors that drive arousal itself. For an erectile dysfunction case caused by vascular issues with intact central arousal, PDE5 inhibitors are the established standard. For an arousal-deficit case where the central signal is the limiting factor, the melanocortin pathway is the more biologically relevant target. The two compound classes do not compete; they address different bottlenecks.

For premenopausal women with hypoactive sexual desire disorder, bremelanotide is the FDA-approved option (Vyleesi). There is no PDE5-inhibitor equivalent approved for low sexual desire in women, which is the niche the peptide fills.

Dosage and routes of administration

The approved Vyleesi dosage is 1.75 mg subcutaneous injection administered at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than eight doses per month. Research protocols have used subcutaneous, intranasal, and intravenous administration at doses ranging from 0.3 mg to 6 mg depending on the endpoint. The peptide is supplied as a lyophilised powder for reconstitution in bacteriostatic water; the autoinjector pen used for Vyleesi delivers the fixed approved dose.

Side effects and safety considerations

The most common adverse event in clinical trials is nausea, reported by approximately 40 percent of subjects after the first dose, declining with subsequent doses. Flushing, headache, and transient blood pressure elevation are also documented. Skin hyperpigmentation (particularly on the face and gums) can occur with chronic dosing because the melanocortin system also drives melanocyte activity, though the off-label dose schedules that cause prominent pigmentation are well above the Vyleesi label. The compound is contraindicated in uncontrolled hypertension and known cardiovascular disease because of the small transient blood pressure rise after each dose.

In rodent safety data, no chronic toxicity has been identified at standard preclinical doses. The off-target risks of long-term melanocortin pathway activation are not fully characterised in humans.

Prescription and legal status

PT-141 (bremelanotide, brand name Vyleesi) is FDA-approved and prescription-only in the United States for the specific indication of acquired generalized hypoactive sexual desire disorder in premenopausal women. It is not approved in Canada as a finished pharmaceutical; Health Canada has not granted a marketing authorisation. Research-grade PT-141 is legal in Canada and the United States as a research chemical sold under research-use-only labelling, distinct from the finished pharmaceutical product. The peptide is not on the World Anti-Doping Agency prohibited list.

Can PT-141 be used by both men and women?

In rodent and primate studies, melanocortin-receptor agonism produces sex-specific behavioural changes in both male and female animals. In human research, bremelanotide has been tested in both populations for sexual arousal endpoints. The FDA approval is limited to premenopausal women with HSDD; off-label use in men is documented in the published literature, including the original Palatin trials of intranasal PT-141 in erectile dysfunction. Researchers studying the peptide in either sex should follow approved IRB protocols.

Comparison with other melanocortin agents

PT-141 sits in a small class of synthetic melanocortin agonists. Melanotan-II is the parent scaffold; setmelanotide (Imcivree) is a related selective MC4R agonist approved for genetic obesity caused by POMC, PCSK1, or LEPR deficiency. The three compounds share receptor pharmacology but differ in selectivity profile and approved indications. Setmelanotide is selective for MC4R and is dosed daily for body-weight effects rather than acutely for arousal effects. Melanotan-II is studied primarily for pigmentation and appetite endpoints. PT-141 is the only compound in the class with an arousal-disorder approval. Researchers comparing the three should account for the selectivity differences and the dose-frequency regimens that go with each.

Where to source research-grade PT-141

Research-grade material requires the same supplier checks as any peptide: a batch-specific Certificate of Analysis from an independent third-party laboratory, HPLC purity at 98 percent or above, mass spectrometry verification of the expected molecular weight (~1025 Da for bremelanotide), and endotoxin and sterility testing for in vivo or cell-culture work. Research-only material is not the same product as the FDA-approved Vyleesi pen.

PT-141 questions

What does the PT-141 peptide do?

PT-141 is a melanocortin receptor agonist that activates MC3R and MC4R in the central nervous system. The downstream effect is increased dopamine release in reward-related brain regions, which drives sexual arousal and sexual desire independently of peripheral vascular mechanisms.

How long does it take for PT-141 to work?

Onset is 30 to 60 minutes after subcutaneous injection; intranasal formulations are faster at 15 to 30 minutes. Duration of effect is approximately 8 to 12 hours.

Do I need a prescription for PT-141?

Yes, the finished pharmaceutical (Vyleesi bremelanotide injection) is prescription-only in the United States. It is not approved as a finished pharmaceutical in Canada. Research-grade material is legal as a research chemical under research-use-only labelling.

Is PT-141 better than Viagra or Cialis?

The two classes target different mechanisms. PDE5 inhibitors are peripheral and act on vascular smooth muscle; PT-141 is central and drives arousal itself. The right tool depends on whether the bottleneck is vascular response or central arousal signal.

What are the side effects of PT-141?

The most common is nausea (~40% after first dose, declining with subsequent doses). Flushing, headache, transient blood pressure elevation, and skin hyperpigmentation with chronic high-dose use are also documented. It is contraindicated in uncontrolled hypertension.

Key data point: Diamond et al. (2004, Annals of the NY Academy of Sciences) reported PT-141 at 10 mg intranasal produced clinically meaningful erectile response in 70% of sildenafil non-responders with psychogenic erectile dysfunction — the first demonstration of a CNS-acting mechanism for erectile response restoration independent of PDE5 inhibition, via MC4R signalling in the hypothalamus.

Summary

PT-141 (bremelanotide) is the only FDA-approved peptide therapy for sexual desire dysfunction. It acts centrally on MC3R and MC4R receptors in the hypothalamus and brainstem, increasing dopamine signalling and driving sexual arousal through a mechanism categorically different from PDE5 inhibitors. The clinical and rodent dataset is well-developed; the safety profile is dominated by transient nausea and minor blood pressure rise; the long-term effects of chronic melanocortin pathway activation are still being characterised. Researchers using research-grade material should source through validated suppliers and follow approved protocols.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption.

Justin Cartier

The Reviv Peptides Research Team is a collective of science writers and researchers dedicated to producing evidence-based, peer-reviewed-grade content about research peptides. Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data — including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank). All content is written in a strict preclinical/laboratory context; none of our editorial material is intended as medical advice. Every guide is reviewed for scientific accuracy against published peer-reviewed literature.